Loading
A phase 3 trial of Tusamitamab ravtansine and Docetaxel in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients is a phase 3 interventional study registered as NCT04154956 by Sanofi, with 389 participants recorded, started 2020-02-06 and due to reach its primary completion in 2023-09-22. Interventions recorded: SAR408701, Docetaxel. Conditions recorded: Non-small Cell Lung Cancer Metastatic.
Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
389 enrolled.
95% CI 3.713 to 6.998; Figures from the ClinicalTrials.gov results section (first posted 2024-11-01), not from a publication · 95% CI 5.520 to 7.359
Source95% CI 11.795 to 14.160; Figures from the ClinicalTrials.gov results section (first posted 2024-11-01), not from a publication · 95% CI 8.936 to 15.244
Source95% CI 16.04 to 28.26; Figures from the ClinicalTrials.gov results section (first posted 2024-11-01), not from a publication · 95% CI 18.13 to 30.84
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS)primary | Tusamitamab Ravtansine | 194 | 5.39 months | 1.143 (0.864 to 1.512) | 0.8204 | link |
| Docetaxel | 195 | 5.85 months | ||||
| Overall Survival (OS)primary | Tusamitamab Ravtansine | 194 | 12.81 months | 0.846 (0.644 to 1.109) | 0.1120 | link |
| Docetaxel | 195 | 11.53 months | ||||
| Objective Response Rate (ORR) | Tusamitamab Ravtansine | 189 | 21.7% | - | 0.6972 | link |
| Docetaxel | 187 | 24.1% |
Shares Tusamitamab ravtansine, Sanofi and the tag pipeline.
Shares Tusamitamab ravtansine, Sanofi, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
Shares Sanofi, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.